Findings were seen for ventricular arrhythmias or death at 1 year for patients with nonischemic cardiomyopathy. Valentina Kutyifa, M.D., Ph.D., from University of Rochester Medical Center in New York, ...
The researchers found that women with nonischemic cardiomyopathy and an implantable cardioverter defibrillator had a lower risk for ventricular tachyarrhythmias or death compared to men. HealthDay ...
The BIO-LIBRA study evaluated contemporary outcomes with an implantable cardioverter defibrillator vs. cardiac resynchronization therapy in patients with nonischemic cardiomyopathy, with an emphasis ...
SAN DIEGO, CA—The observational BIO-LIBRA study, which enrolled nearly 50% women, has revealed important outcome differences by both sex and device type among patients with nonischemic cardiomyopathy ...
Please provide your email address to receive an email when new articles are posted on . A novel implantable cardioverter defibrillator platform may benefit patients with HF not eligible for cardiac ...
SAN DIEGO, CA—Use of a subcutaneous implantable cardioverter-defibrillator (S-ICD) appears to have some advantages over transvenous devices for patients with an ICD indication but no need for pacing, ...
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback